Experimental drug plus radiation shows promise for rare sarcoma

NCT ID NCT06025747

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether the drug abemaciclib, when given with radiation therapy before surgery, can safely shrink high-risk retroperitoneal liposarcomas. About 18 adults with this rare cancer will receive the combination to find the best dose and check for side effects. The goal is to see if this approach makes tumors easier to remove and improves outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib (Verzenio) and radiation therapy
What this could lead to: If successful, this could lead to a new treatment option that shrinks tumors before surgery, potentially improving outcomes for people with this rare sarcoma.
What could go wrong: This is a very early, small phase 1 trial with only 18 participants, so results may not apply broadly. The combination may cause side effects or fail to shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEDIFFERENTIATED LIPOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dedifferentiated liposarcoma liposarcoma retroperitoneal sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEDIFFERENTIATED LIPOSARCOMA LIPOSARCOMA RETROPERITONEAL SARCOMA

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.